Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric
complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes …

Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the
emergence and development of antiangiogenic therapies to eliminate bleeding …

Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of …

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare
multisystem vascular disorder that causes chronic gastrointestinal bleeding, epistaxis, and …

Vascular anomalies represent a diverse group of disorders classified broadly as
malformations or tumors and include the second most common hereditary bleeding disorder …

Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …

Hereditary haemorrhagic telangiectasia (HHT) is a rare vascular multisystemic disease that
leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in …

Hereditary hemorrhagic telangiectasia (HHT) is a rare angiogenic disorder causing chronic
gastrointestinal bleeding, epistaxis, and severe anemia. Pazopanib is an oral multi-kinase …

Abstract Purpose of Review To analyze and compare the effects of epistaxis treatments for
Hereditary Hemorrhagic Telangiectasia (HHT) patients. Recent Findings Of total of 21 …

Over the past two decades, therapies targeting angiogenesis have developed into a major
class of cancer therapeutics. The vascular endothelial growth factor (VEGF) family of …